trimethoprim--sulfamethoxazole-drug-combination has been researched along with Tremor* in 8 studies
1 review(s) available for trimethoprim--sulfamethoxazole-drug-combination and Tremor
Article | Year |
---|---|
Tremors associated with trimethoprim-sulfamethoxazole therapy in a patient with AIDS: case report and review.
Topics: Adult; AIDS-Related Opportunistic Infections; Follow-Up Studies; Humans; Male; Pneumonia, Pneumocystis; Tremor; Trimethoprim, Sulfamethoxazole Drug Combination | 1996 |
7 other study(ies) available for trimethoprim--sulfamethoxazole-drug-combination and Tremor
Article | Year |
---|---|
Severe tremor after cotrimoxazole-induced elevation of venlafaxine serum concentrations in a patient with major depressive disorder.
: We describe a female patient who was an extensive metabolizer of cytochrome P450 isoenzyme (CYP) 2D6 and an intermediate metabolizer of CYP2C19 (genotype: CYP2C19 *1/*2). She exhibited high serum concentrations of venlafaxine and O-desmethylvenlafaxine and developed severe tremor after comedication with cotrimoxazole (sulfamethazole/trimethoprim). Venlafaxine is mainly metabolized by O- and N-demethylation. O-demethylation is catalyzed by the highly polymorphic CYP2D6 and N-demethylation by several enzymes, CYP2C19, CYP2C9, and CYP3A4. The observed overall pharmacokinetic effect was most probably the result of decreased N-demethylation of venlafaxine by (1) reduced expression of CYP2C19 due to a genetic deficit and (2) inhibition of CYP2C9 by cotrimoxazole. Topics: Anti-Infective Agents; Aryl Hydrocarbon Hydroxylases; Cyclohexanols; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Depressive Disorder, Major; Drug Interactions; Female; Humans; Middle Aged; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Tremor; Trimethoprim, Sulfamethoxazole Drug Combination; Venlafaxine Hydrochloride | 2013 |
Tremors and chorea induced by trimethoprim-sulfamethoxazole in a child with Pneumocystis pneumonia.
A 1.5-year-old girl developed high frequency tremors and chorea after receiving a dose of 120 mg/kg/d trimethoprim-sulfamethoxazole (TMP-SMX) for the treatment of Pneumocystis pneumonia. The child was human immunodeficiency virus-negative but immunocompromised because of prolonged immunosuppressive therapy. These symptoms disappeared 3 days after TMP-SMX was discontinued. Pediatricians should be aware of tremors and chorea among the potential adverse effects of high doses of TMP-SMX. Topics: Anti-Infective Agents; Chorea; Female; Humans; Infant; Pneumonia, Pneumocystis; Tremor; Trimethoprim, Sulfamethoxazole Drug Combination | 2005 |
[Oligoarthritis, trembling and chronic diarrhea in a 54 years old male].
Topics: Anti-Infective Agents; Arthritis; Chronic Disease; Diarrhea; Duodenum; Gastrointestinal Transit; Humans; Intestinal Mucosa; Male; Middle Aged; Tomography, X-Ray Computed; Treatment Outcome; Tremor; Trimethoprim, Sulfamethoxazole Drug Combination; Ultrasonography; Whipple Disease | 2003 |
Trimethoprim-sulfamethoxazole-induced tremor in an immunocompetent patients.
Trimethoprim-sulfamethoxazole (TMP-SMX) is a widely administered antibiotic that is well tolerated by most patients. Hypersensitivity reactions and gastrointestinal intolerance are the most common adverse events associated with it. Central nervous system adverse effects such as tremors are less common and occur primarily in patients with acquired immune deficiency syndrome. A 29-year-old immunocompetent man developed a tremor while taking TMP-SMX. The tremor resolved within 2 days after the drug was discontinued. Topics: Adult; Anti-Infective Agents; Enterobacteriaceae Infections; Humans; Immunocompetence; Male; Postoperative Complications; Tremor; Trimethoprim, Sulfamethoxazole Drug Combination | 1999 |
Tremor caused by trimethoprim-sulfamethoxazole in a patient with AIDS.
Topics: AIDS-Related Opportunistic Infections; Anti-Infective Agents; Humans; Male; Middle Aged; Pneumonia, Pneumocystis; Tremor; Trimethoprim, Sulfamethoxazole Drug Combination | 1997 |
Adverse effects of trimethoprim-sulfamethoxazole in a child with dihydropteridine reductase deficiency.
A child with dihydropteridine reductase (DHPR) deficiency developed signs of dopamine insufficiency after being given trimethoprim-sulfamethoxazole (TMP-SMX). She recovered function after the antibiotic was stopped, which suggests that it adversely influenced dopamine metabolism in the CNS. The authors speculate that TMP, a dihydrofolate reductase inhibitor, was the major cause of the patient's deterioration, and suggest that it and other dihydrofolate inhibitors, notably methotrexate, are contra-indicated for patients with DHPR deficiency. Topics: Child, Preschool; Dopamine; Epinephrine; Female; Humans; NADH, NADPH Oxidoreductases; Norepinephrine; Phenylalanine; Phenylketonurias; Sinusitis; Tremor; Trimethoprim, Sulfamethoxazole Drug Combination | 1990 |
Tremor induced by trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome (AIDS).
Topics: Acquired Immunodeficiency Syndrome; Adult; Ataxia; Drug Combinations; Drug Eruptions; Emotions; Humans; Male; Pneumonia, Pneumocystis; Reflex, Abnormal; Sulfamethoxazole; Tremor; Trimethoprim; Trimethoprim, Sulfamethoxazole Drug Combination | 1988 |